<DOC>
	<DOCNO>NCT00483782</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . It yet know whether give carboplatin paclitaxel together bevacizumab effective carboplatin paclitaxel alone treat patient ovarian epithelial cancer , fallopian tube cancer , primary peritoneal cavity cancer . PURPOSE : This randomized phase III trial study carboplatin , paclitaxel , bevacizumab see well work compare carboplatin paclitaxel alone treat patient newly diagnose ovarian epithelial cancer , fallopian tube cancer , primary peritoneal cavity cancer .</brief_summary>
	<brief_title>Carboplatin Paclitaxel With Without Bevacizumab Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer , Fallopian Tube Cancer , Primary Peritoneal Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival overall survival patient newly diagnose ovarian epithelial , fallopian tube , primary peritoneal cavity cancer treat carboplatin paclitaxel v without bevacizumab . Secondary - Compare response rate patient treat regimen . - Compare duration tumor response patient treat regimen . - Compare biological progression-free interval , measure increase CA 125 level , patient treat regimen . - Compare safety ( e.g. , adverse event , laboratory result , performance status ) regimens patient . - Compare quality life patient treat regimen . - Compare cost-effectiveness regimen patient . OUTLINE : This multicenter , open-label , randomize , control study . Patients stratify accord FIGO stage ( stage I-III residual disease ≤ 1 cm v stage I-III residual disease &gt; 1 cm v stage IV disease ) , intend time start chemotherapy surgery ( ≤ 4 week vs &gt; 4 week ) , participate center . Patients randomize 1 2 treatment arm . - Arm I ( control ) : Patients receive paclitaxel IV 3 hour follow carboplatin IV 30-60 minute day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive bevacizumab IV 30-90 minute follow paclitaxel IV 3 hour carboplatin IV 30-60 minute day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients continue receive bevacizumab alone every 3 week 12 course . Quality life assess baseline , every course , every 6 week 1 year , every 3 month disease progression 2 year , 3 year . Health economic data assess periodically , include day inpatient hospitalization visit , outpatient visit , use anticancer therapy . After completion study treatment , patient follow every 3-6 month 5 year annually thereafter . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , fallopian tube , primary peritoneal cavity cancer Newly diagnose disease Meets 1 follow stag criterion : Highrisk stage I IIA disease ( grade 3 disease clear cell carcinoma ) Stage IIBIV disease ( grades histological type ) Must undergone initial surgery ( e.g. , debulking cytoreductive surgery biopsy patient stage IV disease ) within past 6 week Patients stage IV disease initial surgical debulking appropriate eligible provide follow criterion meet : Stage IV disease diagnose histology No plan surgery prior disease progression , include interval debulking surgery Patients prior earlystage ovarian epithelial fallopian tube carcinoma treat surgery alone eligible time diagnosis abdominopelvic recurrence provide interval cytoreductive therapy plan prior disease progression Synchronous primary endometrial carcinoma past history primary endometrial carcinoma allow provide follow criterion meet : Disease ≤ stage IB No superficial myometrial invasion No lymphovascular invasion Not poorly differentiate ( i.e. , grade 3 , papillary serous , clear cell disease ) Measurable nonmeasurable disease No ovarian nonepithelial cancer , include malignant mixed Müllerian tumor No borderline tumor ( e.g. , tumor low malignant potential ) No history clinical suspicion brain metastasis spinal cord compression CT scan MRI brain mandatory ( within 4 week prior randomization ) case suspect brain metastasis Spinal MRI mandatory ( within 4 week prior randomization ) case suspect spinal cord compression PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 12 week ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL ( posttransfusion ) INR ≤ 1.5 APTT ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN ALT AST ≤ 2.5 time ULN Creatinine ≤ 2.0 mg/dL Proteinuria ≤ 1+ urine dipstick OR ≤ 1 g 24hour urine collection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 6 week completion study therapy No significant traumatic injury within past 4 week No cerebrovascular accident , transient ischemic attack , subarachnoid hemorrhage within past 6 month No malignancy within past 5 year except adequately treat carcinoma situ cervix , and/or basal cell skin cancer , and/or early endometrial carcinoma No preexist sensory motor neuropathy ≥ grade 2 No history evidence CNS disease ( e.g. , uncontrolled seizure ) neurological examination unless adequately treat standard medical therapy No history evidence thrombotic hemorrhagic disorder No uncontrolled hypertension ( i.e. , blood pressure &gt; 150/100 mm Hg despite antihypertensive therapy ) No know hypersensitivity bevacizumab excipients , chemotherapy , Cremophor EL No nonhealing wound , ulcer , bone fracture Patients granulate incision heal secondary intention evidence facial dehiscence infection eligible require three weekly wound examinations No clinically significant cardiovascular disease , include follow : Myocardial infarction unstable angina within past 6 month New York Heart Association class IIIV congestive heart failure Poorly control cardiac arrhythmia despite medication Ratecontrolled atrial fibrillation allow Peripheral vascular disease ≥ grade 3 ( i.e. , symptomatic interfering activity daily live require repair revision ) No evidence disease condition , metabolic dysfunction , physical examination finding , laboratory finding would contraindicate use investigational drug put patient highrisk treatmentrelated complication PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior surgery open biopsy No prior systemic therapy ovarian cancer ( e.g. , chemotherapy , monoclonal antibody therapy , tyrosine kinase inhibitor therapy , hormonal therapy ) Prior adjuvant chemotherapy allow malignancy ( e.g. , breast colorectal carcinoma ) malignancy diagnose 5 year ago evidence subsequent recurrence No prior mouse CA 125 antibody No prior radiotherapy abdomen pelvis More 10 day since prior concurrent chronic use acetylsalicylic acid ( &gt; 325 mg/day ) Lowdose ( &lt; 325 mg/day ) acetylsalicylic acid allow More 10 day since prior concurrent fulldose oral parenteral anticoagulant thrombolytic agent therapeutic purpose Use therapy line patency allow provide INR &lt; 1.5 More 30 day since prior concurrent investigational agent participation another clinical trial No concurrent systemic antitumor agents No concurrent surgery No concurrent maintenance chemotherapy intraperitoneal chemotherapy ( include cytotoxic chemotherapy )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>Brenner tumor</keyword>
	<keyword>ovarian carcinosarcoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>stage IA ovarian epithelial cancer</keyword>
	<keyword>stage IB ovarian epithelial cancer</keyword>
	<keyword>stage IC ovarian epithelial cancer</keyword>
	<keyword>stage IIA ovarian epithelial cancer</keyword>
	<keyword>stage IIB ovarian epithelial cancer</keyword>
	<keyword>stage IIC ovarian epithelial cancer</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
	<keyword>stage IA fallopian tube cancer</keyword>
	<keyword>stage IB fallopian tube cancer</keyword>
	<keyword>stage IC fallopian tube cancer</keyword>
	<keyword>stage IIA fallopian tube cancer</keyword>
	<keyword>stage IIB fallopian tube cancer</keyword>
	<keyword>stage IIC fallopian tube cancer</keyword>
	<keyword>stage IIIA fallopian tube cancer</keyword>
	<keyword>stage IIIB fallopian tube cancer</keyword>
	<keyword>stage IIIC fallopian tube cancer</keyword>
	<keyword>stage IV fallopian tube cancer</keyword>
	<keyword>stage IA primary peritoneal cavity cancer</keyword>
	<keyword>stage IB primary peritoneal cavity cancer</keyword>
	<keyword>stage IC primary peritoneal cavity cancer</keyword>
	<keyword>stage IIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IV primary peritoneal cavity cancer</keyword>
</DOC>